RxDoctor Payments Data

John Adams, DO

Medical Oncology · Arlington, TXNPI 1548262900

Payments from drug & device makers

$83,863in general payments, 2019–2025

Across 209 payments — averaging $401.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$25K
  • E.r. Squibb & Sons, L.L.C.$16K
  • Mirati Therapeutics, Inc.$15K
  • Novocure Inc.$15K
  • AstraZeneca$8K
  • Novartis$1K
  • plus $4K from 47 others
$2,700in research payments, 2019–2025

Across 3 payments — averaging $900.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Janssen Scientific Affairs, LLC$3K

What the payments were for

  • Food & beverage$2,73465%
  • Education$3829%
  • Other$1,09726%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$83,863 in reported general payments places this provider in the 50th percentile of 495 medical oncology providers in Texas.

See all medical oncology providers in Texas

Medicare billing

Part B allowed, 2024
$1,900,803
Medicare patients
352
Services billed
89,608

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CalquenceAcalabrutinib Maleate27$412,416
RevlimidLenalidomide13$217,187
Lenalidomide15$201,574
BrukinsaZanubrutinib12$181,655
Imatinib Mesylate15$24,360
AranespDarbepoetin Alfa In Polysorbat11$19,316
XareltoRivaroxaban19$14,068
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen73$3,802
Megestrol Acetate22$1,983
Anastrozole121$1,112
Hydroxyurea67$980
Morphine Sulfate ErMorphine Sulfate22$553
Dexamethasone33$498
Gabapentin17$459
Bicalutamide22$442

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaCalquence$8,497$412,41627 claims
Bristol Myers SquibbRevlimid$121$217,18713 claims
AmgenAranesp$43$19,31611 claims
Johnson & JohnsonXarelto$121$14,06819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 495 medical oncology providers in Texas.

Other medical oncology in Arlington

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →